Invention Grant
![Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of MGLUR2 receptors](/docs/US/2018-06-26/US10005786B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of MGLUR2 receptors
-
Application No.: US15500600Application Date: 2015-07-30
-
Publication No.: US10005786B2Publication Date: 2018-06-26
- Inventor: Sergio-Alvar Alonso-de Diego , Michiel Luc Maria Van Gool , Óscar Delgado-González , José Ignacio Andrés-Gil , Andrés Avelino Trabanco-Suárez
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE
- Assignee: JANSSEN PHARMACEUTICA NV
- Current Assignee: JANSSEN PHARMACEUTICA NV
- Current Assignee Address: BE
- Priority: EP14179598 20140801
- International Application: PCT/EP2015/067530 WO 20150730
- International Announcement: WO2016/016380 WO 20160204
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D487/04 ; A61K31/506
![Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of MGLUR2 receptors](/abs-image/US/2018/06/26/US10005786B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
Public/Granted literature
Information query
IPC分类:
